New tricks for an old glob

Bayer AG thinks that one of its older biologics, human immunoglobulin intravenous (IGIV), could be a successful therapeutic for relapsing-remitting multiple sclerosis. Recently, the company completed enrollment of 120 RRMS patients in a one-year, double-blind, placebo-controlled, international